Q3 2023 · —
Revenue—
Net Income-$22.85M-$22.85M no prior Q3 2022 on fileN/M vs Q2 2023
EPS Diluted-$38.23-$38.23 no prior Q3 2022 on fileno prior Q2 2023 on file
Operating Income-$9,530,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q3 2022 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR